Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05397769
What this trial is testing

Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.

Who this might be right for
Locally Advanced Nasopharyngeal CarcinomaEnvafolimabInduction Chemotherapy+1 more
Sun Yat-sen University 36
Post-approval studies (Phase 4)Study completedNCT03134456
What this trial is testing

Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX

Who this might be right for
Metastatic Non-Small Cell Lung Carcinoma
Samsung Medical Center 50
Testing effectiveness (Phase 2)UnknownNCT05266937
What this trial is testing

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Who this might be right for
Metastatic Breast CancerTriple Negative Breast CancerPD-L1 Gene Mutation
Consorzio Oncotech 49
Large-scale testing (Phase 3)Study completedNCT02409342
What this trial is testing

Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 572
Not applicableLooking for participantsNCT05552846
What this trial is testing

Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy

Who this might be right for
Small-cell Lung Cancer
Ruijin Hospital 104
Testing effectiveness (Phase 2)Study completedNCT03212469
What this trial is testing

A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer

Who this might be right for
Head and Neck Squamous Cell CarcinomaLung CancerOesophageal Cancer
Gustave Roussy, Cancer Campus, Grand Paris 54
Not applicableUnknownNCT03559803
What this trial is testing

A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix Cancer

Who this might be right for
Cervical Cancer
Sichuan University 58
Testing effectiveness (Phase 2)Ended earlyNCT03382912
What this trial is testing

Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Eli Lilly and Company 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT05013450
What this trial is testing

Dupilumab_Metastatic NSCLC

Who this might be right for
Metastatic Non-small Cell Lung Cancer
Thomas Marron 33
Testing effectiveness (Phase 2)Looking for participantsNCT06288360
What this trial is testing

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Who this might be right for
Cervical CancerLocally Advanced Cervical CancerPD-L1 Negative+1 more
Tongji Hospital 40
Large-scale testing (Phase 3)Study completedNCT03469960
What this trial is testing

Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

Who this might be right for
Non-Small Cell Lung Cancer Metastatic
Intergroupe Francophone de Cancerologie Thoracique 265
Testing effectiveness (Phase 2)UnknownNCT04631731
What this trial is testing

Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity

Who this might be right for
Lung Cancer, Nonsmall CellRenal Cell CarcinomaMelanoma+4 more
Western Sydney Local Health District 200
Testing effectiveness (Phase 2)Looking for participantsNCT04683679
What this trial is testing

Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerBreast Cancer+1 more
Memorial Sloan Kettering Cancer Center 34
Testing effectiveness (Phase 2)Active Not RecruitingNCT05426005
What this trial is testing

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer Stage IVMismatch Repair-deficient (dMMR)Microsatellite Instability-high (MSI-H)
Sun Yat-sen University 28
Early research (Phase 1)UnknownNCT04608786
What this trial is testing

A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer

Who this might be right for
Biliary Tract Cancer
Lee's Pharmaceutical Limited 10
Early research (Phase 1)UnknownNCT05263180
What this trial is testing

EMB-09 in Participants With Advanced or Metastatic Solid Tumors.

Who this might be right for
Advanced Solid Tumor
Shanghai EpimAb Biotherapeutics Co., Ltd. 30
Not applicableUnknownNCT04790955
What this trial is testing

Effect of Combination Therapy on SCLC After Initial Treatment Failure

Who this might be right for
Small-cell Lung Cancer
First Affiliated Hospital of Harbin Medical University 48
Testing effectiveness (Phase 2)Ended earlyNCT04862455
What this trial is testing

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Who this might be right for
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center 14
Testing effectiveness (Phase 2)Ended earlyNCT04152863
What this trial is testing

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Who this might be right for
Advanced/Metastatic Melanoma
Merck Sharp & Dohme LLC 85
Large-scale testing (Phase 3)Looking for participantsNCT06627647
What this trial is testing

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
AstraZeneca 1,160
Next Page